NCT03128866Active, not recruitingEarly phase 1
Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 21 Apr 2017
- Start date
- 19 May 2017
- Primary completion date
- 31 May 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT03128866
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 80
- From 19 May 2017 to the primary completion date, 31 May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with a history of genetic prothrombotic state
- Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
- Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction
- Patients will not be eligible if they have a history of color vision defects
- Patients will not be eligible if they have a history of retinal vein or artery occlusion
- Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
- Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
- Patients will not be eligible if they present or have a history of seizure disorder
Lab values
- Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73m2)
Other
- Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment
Who the study is looking for
- Both pediatric and adult patients can be eligible to participate
- Cognitively impaired and non-English speakers can be eligible to participate.
- Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.